CN101605540A - 使用mek抑制剂的方法 - Google Patents

使用mek抑制剂的方法 Download PDF

Info

Publication number
CN101605540A
CN101605540A CNA2007800513551A CN200780051355A CN101605540A CN 101605540 A CN101605540 A CN 101605540A CN A2007800513551 A CNA2007800513551 A CN A2007800513551A CN 200780051355 A CN200780051355 A CN 200780051355A CN 101605540 A CN101605540 A CN 101605540A
Authority
CN
China
Prior art keywords
amino
phenyl
methoxy
fluoro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800513551A
Other languages
English (en)
Chinese (zh)
Inventor
彼得·拉姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Priority to CN201510422958.4A priority Critical patent/CN105106199A/zh
Priority to CN202010431292.XA priority patent/CN111643496A/zh
Publication of CN101605540A publication Critical patent/CN101605540A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007800513551A 2006-12-14 2007-12-14 使用mek抑制剂的方法 Pending CN101605540A (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201510422958.4A CN105106199A (zh) 2006-12-14 2007-12-14 使用mek抑制剂的方法
CN202010431292.XA CN111643496A (zh) 2006-12-14 2007-12-14 使用mek抑制剂的方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87541206P 2006-12-14 2006-12-14
US60/875,412 2006-12-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN201510422958.4A Division CN105106199A (zh) 2006-12-14 2007-12-14 使用mek抑制剂的方法
CN202010431292.XA Division CN111643496A (zh) 2006-12-14 2007-12-14 使用mek抑制剂的方法

Publications (1)

Publication Number Publication Date
CN101605540A true CN101605540A (zh) 2009-12-16

Family

ID=39322626

Family Applications (3)

Application Number Title Priority Date Filing Date
CNA2007800513551A Pending CN101605540A (zh) 2006-12-14 2007-12-14 使用mek抑制剂的方法
CN202010431292.XA Pending CN111643496A (zh) 2006-12-14 2007-12-14 使用mek抑制剂的方法
CN201510422958.4A Pending CN105106199A (zh) 2006-12-14 2007-12-14 使用mek抑制剂的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202010431292.XA Pending CN111643496A (zh) 2006-12-14 2007-12-14 使用mek抑制剂的方法
CN201510422958.4A Pending CN105106199A (zh) 2006-12-14 2007-12-14 使用mek抑制剂的方法

Country Status (11)

Country Link
US (1) US7999006B2 (https=)
EP (1) EP2101759B1 (https=)
JP (2) JP5311673B2 (https=)
CN (3) CN101605540A (https=)
AU (1) AU2007334402B2 (https=)
CA (1) CA2671982C (https=)
ES (1) ES2703723T3 (https=)
HK (1) HK1218256A1 (https=)
PL (1) PL2101759T3 (https=)
TR (1) TR201900306T4 (https=)
WO (1) WO2008076415A1 (https=)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464701A (zh) * 2010-11-08 2012-05-23 上海医药工业研究院 一类新型化合物、其制备方法及用途
WO2012130160A1 (zh) * 2011-03-31 2012-10-04 中国人民解放军军事医学科学院毒物药物研究所 含吖丁啶环的氨基吡啶类衍生物及其用途
CN102964308A (zh) * 2012-11-30 2013-03-13 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN103841976A (zh) * 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
CN104725352A (zh) * 2015-03-19 2015-06-24 上海皓元生物医药科技有限公司 一种3-(哌啶-2-基)-氮杂环丁烷-3-醇的衍生物的合成方法及其用途
CN104736533A (zh) * 2012-08-17 2015-06-24 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
CN106496232A (zh) * 2016-09-22 2017-03-15 南方医科大学 一种具有抗肿瘤活性的1‑(2‑四氢吡喃)‑1H‑吡唑并[3,4‑d]嘧啶类化合物及其制备方法
WO2017096996A1 (zh) * 2015-12-09 2017-06-15 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN104837826B (zh) * 2012-10-12 2018-07-27 埃克塞里艾克西斯公司 制备用于治疗癌症的化合物的新型方法
CN110013478A (zh) * 2012-03-19 2019-07-16 豪夫迈·罗氏有限公司 用于抗肿瘤试剂施用的方法
CN111936487B (zh) * 2018-01-26 2024-07-09 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005028469A1 (en) 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
ES2364495T3 (es) 2005-02-03 2011-09-05 The General Hospital Corporation Método para tratar cáncer resistente a gefitinib.
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
CN101528231A (zh) * 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP2262772B8 (en) 2008-04-16 2013-03-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinoline derivatives as axl kinase inhibitors
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
ES2692769T3 (es) 2008-06-17 2018-12-05 Wyeth Llc Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina
UA107183C2 (uk) 2008-08-04 2014-12-10 Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
JP2012512877A (ja) * 2008-12-18 2012-06-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング セロトニン５−ｈｔ２ｂ受容体阻害剤
SG173014A1 (en) 2009-01-16 2011-08-29 Exelixis Inc Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quin0lin-4-yl] oxy}phenyl)-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer
CN101836991B (zh) * 2009-03-19 2013-05-22 鼎泓国际投资（香港）有限公司 含有索拉非尼、cMet抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
ES2578990T3 (es) * 2009-03-21 2016-08-03 Sunshine Lake Pharma Co., Ltd. Derivados de amino éster, sales de los mismos y métodos de uso
UA108618C2 (uk) * 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2311809A1 (en) * 2009-10-16 2011-04-20 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Quinolinyloxyphenylsulfonamides
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
CN103038364A (zh) 2010-03-09 2013-04-10 达纳－法伯癌症研究所公司 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法
EP2593090B1 (en) 2010-07-16 2021-10-13 Exelixis, Inc. C-met modulator pharmaceutical compositions
CA2812750C (en) 2010-09-27 2020-10-06 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases
CN102093421B (zh) 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
JP2014505109A (ja) 2011-02-10 2014-02-27 エクセリクシス， インク． キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) * 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
GEP201606523B (en) 2011-09-22 2016-08-10 Exelixis Inc Method for treating osteoporosis
DK2768796T3 (da) 2011-10-20 2020-02-24 Exelixis Inc Fremgangsmåde til fremstilling af quinolin-derivater
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
US20140200255A1 (en) 2012-03-19 2014-07-17 Brian Higgins Method for administration
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
WO2013182668A1 (en) 2012-06-08 2013-12-12 F. Hoffmann-La Roche Ag Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
CN103804364A (zh) * 2012-11-06 2014-05-21 韩冰 一类治疗缺血性脑损伤的化合物及其用途
AU2014232714B2 (en) 2013-03-15 2018-07-19 Exelixis, Inc. Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
EP2981263B1 (en) 2013-04-04 2022-06-29 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
CA2923835C (en) * 2013-09-11 2022-11-29 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
KR102354963B1 (ko) 2014-02-14 2022-01-21 엑셀리시스, 인코포레이티드 N-｛4-[(6,7-다이메톡시퀴놀린-4-일)옥시]페닐｝-n'-(4-플루오로페닐) 사이클로프로판-1,1-다이카복스아마이드의 결정질 고체 형태, 제조 방법 및 사용 방법
EA201691850A1 (ru) 2014-03-17 2016-12-30 Экселиксис, Инк. Дозирование составов, содержащих кабозантиниб
ES2929888T3 (es) 2014-07-31 2022-12-02 Exelixis Inc Procedimiento para preparar cabozantinib marcado con flúor 18 y sus análogos
BR112017002318A2 (pt) 2014-08-05 2018-07-17 Exelixis, Inc. combinações de fármacos para tratar mieloma múltiplo.
CN106290600B (zh) * 2015-06-12 2019-01-01 北京康辰药业股份有限公司 一种用液相色谱法分离康尼替尼及有关物质的方法
AR105483A1 (es) * 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
RU2748549C2 (ru) 2016-04-15 2021-05-26 Экселиксис, Инк. Способ лечения почечно-клеточного рака с использованием n-(4-(6,7-диметоксихинолин-4-илокси)фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, (2s)-гидроксибутандиоата
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
WO2019025250A1 (en) 2017-08-04 2019-02-07 Basf Se SUBSTITUTED TRIFLUOROMETHYLOXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI
GB201717809D0 (en) * 2017-10-30 2017-12-13 Azad Pharmaceutical Ingredients Ag Process for the production of cobimetinib
WO2020045535A1 (ja) * 2018-09-01 2020-03-05 富士フイルム株式会社 感活性光線性又は感放射線性樹脂組成物、感活性光線性又は感放射線性膜、パターン形成方法、フォトマスク、電子デバイスの製造方法、及び化合物
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN116583502A (zh) 2020-09-03 2023-08-11 欧瑞夏治疗有限公司 二环-杂环衍生物及其作为食欲素-2受体激动剂的用途
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
CN114957331A (zh) * 2022-04-22 2022-08-30 北京康辰药业股份有限公司 磷酸酯取代的环丙酰胺衍生喹唑啉类化合物的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
WO2007044515A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510139A (en) * 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
CA2186947A1 (en) * 1994-04-01 1995-10-12 Kazuo Ueda Oxime derivative and bactericide containing the same as active ingredients
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (en) 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
NZ501276A (en) 1997-07-01 2000-10-27 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors in treating proliferative disorders
CA2290509A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
US6974878B2 (en) * 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
AU2180500A (en) 1998-12-15 2000-07-03 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
AU776788C (en) 1998-12-16 2005-10-27 Warner-Lambert Company Treatment of arthritis with MEK inhibitors
PL348326A1 (en) 1998-12-22 2002-05-20 Warner Lambert Co Combination chemotherapy
JP2002534380A (ja) 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
AU2203800A (en) 1999-01-07 2000-07-24 Warner-Lambert Company Antiviral method using mek inhibitors
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
EP1150950A2 (en) 1999-01-13 2001-11-07 Warner-Lambert Company Anthranilic acid derivatives
CA2355470C (en) 1999-01-13 2008-09-30 Warner-Lambert Company Benzoheterocycles and their use as mek inhibitors
HUP0105092A3 (en) 1999-01-13 2003-12-29 Warner Lambert Co 1-heterocycle substituted diarylamines and medicaments containing them
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
JP2003504401A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いる慢性疼痛の治療方法
EP1202732A2 (en) 1999-07-16 2002-05-08 Warner-Lambert Company Llc Method for treating chronic pain using mek inhibitors
JP2003504400A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤を用いた慢性痛の治療方法
CA2377092A1 (en) 1999-07-16 2001-01-25 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
DE60040676D1 (de) 1999-09-17 2008-12-11 Millennium Pharm Inc BENZAMIDE UND ÄHNLICHE INHIBITOREN VON FAKTOR Xa
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
US7105682B2 (en) * 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
IL149462A0 (en) 2001-05-09 2002-11-10 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
DE10141266A1 (de) * 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
JP2003192592A (ja) 2001-10-17 2003-07-09 Sankyo Co Ltd 医薬組成物
CN1568184A (zh) 2001-10-31 2005-01-19 辉瑞产品公司 烟碱乙酰胆碱受体激动剂在治疗多动腿综合征中的用途
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
EP1467968A1 (en) 2002-01-23 2004-10-20 Warner-Lambert Company LLC N-(4-substituted phenyl)-anthranilic acid hydroxamate esters
EP1482944A4 (en) 2002-03-13 2006-04-19 Array Biopharma Inc NZ ALKYL BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
EP1515727A4 (en) 2002-06-11 2009-04-08 Merck & Co Inc (HALO-BENZO CARBONYL) HETEROBICYCLIC P38 KINASE INHIBITION
EP2280003B1 (en) 2002-07-15 2014-04-02 Symphony Evolution, Inc. Process for preparing receptor-type kinase modulators
AP2005003338A0 (en) 2002-12-04 2005-06-30 Univ Cape Town And South Afric A method for production of HIV-1 Gag virus-like particles
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
CA2517517C (en) * 2003-03-03 2012-12-18 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EP1641804A1 (en) * 2003-06-20 2006-04-05 Celltech R & D Limited Thienopyridone derivatives as kinase inhibitors
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
WO2005007616A1 (en) 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
US20050049276A1 (en) * 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
CA2532067C (en) 2003-07-24 2010-12-21 Stephen Douglas Barrett N-methyle-substituted benzamidazoles
US7538120B2 (en) * 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US8084645B2 (en) * 2003-09-19 2011-12-27 Chugai Seiyaku Kabushiki Kaisha 4-phenylamino-benzaldoxime derivatives and uses thereof as mitogen-activated protein kinase kinase (MEK) inhibitors
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
CA2546353A1 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Bicyclic inhibitors of mek and methods of use thereof
CA2547804A1 (en) * 2003-12-08 2005-06-30 F. Hoffmann-La Roche Ag Novel thiazole derivatives
MY144232A (en) 2004-07-26 2011-08-15 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
AR050084A1 (es) 2004-07-27 2006-09-27 Novartis Ag Derivados de bencimidazolona como inhibidores de hsp90
MX2007004781A (es) 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
AU2005322855B2 (en) 2004-12-30 2012-09-20 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
CN101528231A (zh) * 2006-08-16 2009-09-09 埃克塞利希斯股份有限公司 在癌症的治疗中使用pi3k和mek调控剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
WO2007044515A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102464701B (zh) * 2010-11-08 2015-10-21 上海医药工业研究院 一类新型化合物、其制备方法及用途
CN102464701A (zh) * 2010-11-08 2012-05-23 上海医药工业研究院 一类新型化合物、其制备方法及用途
WO2012130160A1 (zh) * 2011-03-31 2012-10-04 中国人民解放军军事医学科学院毒物药物研究所 含吖丁啶环的氨基吡啶类衍生物及其用途
CN102718750A (zh) * 2011-03-31 2012-10-10 中国人民解放军军事医学科学院毒物药物研究所 含吖啶环的氨基吡啶类衍生物及其用途
CN102718750B (zh) * 2011-03-31 2015-03-11 中国人民解放军军事医学科学院毒物药物研究所 含吖啶环的氨基吡啶类衍生物及其用途
US9682082B2 (en) 2011-04-01 2017-06-20 Genentech, Inc. Combinations of AKT and MEK inhibitor compounds, and methods of use
CN110433165A (zh) * 2011-04-01 2019-11-12 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
CN103841976A (zh) * 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
CN110013478A (zh) * 2012-03-19 2019-07-16 豪夫迈·罗氏有限公司 用于抗肿瘤试剂施用的方法
CN104736533A (zh) * 2012-08-17 2015-06-24 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
CN104736533B (zh) * 2012-08-17 2016-12-07 癌症治疗合作研究中心有限公司 Vegfr3抑制剂
CN108948043A (zh) * 2012-10-12 2018-12-07 埃克塞里艾克西斯公司 制备用于治疗癌症的化合物的新型方法
CN104837826B (zh) * 2012-10-12 2018-07-27 埃克塞里艾克西斯公司 制备用于治疗癌症的化合物的新型方法
CN108948043B (zh) * 2012-10-12 2021-05-04 埃克塞里艾克西斯公司 制备用于治疗癌症的化合物的新型方法
CN102964308A (zh) * 2012-11-30 2013-03-13 中国药科大学 新型嘧啶类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN104725352A (zh) * 2015-03-19 2015-06-24 上海皓元生物医药科技有限公司 一种3-(哌啶-2-基)-氮杂环丁烷-3-醇的衍生物的合成方法及其用途
WO2017096996A1 (zh) * 2015-12-09 2017-06-15 苏州明锐医药科技有限公司 卡比替尼的制备方法
US10407403B2 (en) 2015-12-09 2019-09-10 Suzhou Miracpharma Technology Co., Ltd. Preparation method of cobimetinib
CN106496232B (zh) * 2016-09-22 2018-11-09 南方医科大学 一种具有抗肿瘤活性的1-(2-四氢吡喃)-1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法
CN106496232A (zh) * 2016-09-22 2017-03-15 南方医科大学 一种具有抗肿瘤活性的1‑(2‑四氢吡喃)‑1H‑吡唑并[3,4‑d]嘧啶类化合物及其制备方法
CN111936487B (zh) * 2018-01-26 2024-07-09 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物

Also Published As

Publication number Publication date
TR201900306T4 (tr) 2019-02-21
WO2008076415A1 (en) 2008-06-26
US20080166359A1 (en) 2008-07-10
CN105106199A (zh) 2015-12-02
US7999006B2 (en) 2011-08-16
CN111643496A (zh) 2020-09-11
CA2671982A1 (en) 2008-06-26
EP2101759A1 (en) 2009-09-23
CA2671982C (en) 2016-01-26
EP2101759B1 (en) 2018-10-10
JP2013151569A (ja) 2013-08-08
JP2010513288A (ja) 2010-04-30
AU2007334402B2 (en) 2014-02-13
AU2007334402A1 (en) 2008-06-26
PL2101759T3 (pl) 2019-05-31
HK1218256A1 (zh) 2017-02-10
JP5311673B2 (ja) 2013-10-09
ES2703723T3 (es) 2019-03-12

Similar Documents

Publication Publication Date Title
CN101605540A (zh) 使用mek抑制剂的方法
JP7187729B2 (ja) Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
US11795164B2 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
US10457669B2 (en) Benzolactam compounds as protein kinase inhibitors
US11261171B1 (en) Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
CN101365676B (zh) 作为用于治疗增生性疾病的mek抑制剂的吖丁啶
EP3517536B1 (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
JP2010513288A5 (https=)
TW201838966A (zh) 取代的二氫茚－４－甲醯胺及其類似物以及其使用方法
CN111527090B (zh) 作为p2x3抑制剂的吡唑并-吡咯并-嘧啶-二酮衍生物
TW201838981A (zh) 嘧啶基-吡啶氧基-萘基化合物以及治療ire1相關之疾病及病症的方法
TW202136237A (zh) RORγt抑制劑及其製備方法和用途
RU2797295C1 (ru) Изоиндолиноновые ингибиторы взаимодействия mdm2-p53, обладающие противораковой активностью
WO2025235389A1 (en) P53 modulators
HK1134784B (en) Methods of using mek inhibitors
HK1134784A (en) Methods of using mek inhibitors
AU2013204026A1 (en) Methods of using MEK inhibitors
BR112018005936B1 (pt) Inibidores de isoindolinona da interação de mdm2-p53, composição farmacêutica, seus usos e processo para a preparação do composto

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091216

WD01 Invention patent application deemed withdrawn after publication